

## Special Issue

# Personalized Medicine in Otolaryngology: Novel Prognostic Markers

### Message from the Guest Editors

In recent years, the field of otolaryngology has seen massive improvements in terms of novel treatment options, ranging from checkpoint inhibitors for recurrent and/or metastatic head and neck squamous cell carcinoma, biological treatment for patients with nasal polyposis, to novel active bone-conduction hearing implants for patients with sensorineural, conductive, and mixed hearing loss. In order to further facilitate patient-selection and improve outcomes for patients, efforts have to be undertaken to identify easily obtainable prognostic markers. This Special Issue aims to collate papers that underscore recent findings and perspectives on future developments in terms of personalized treatments for patients with otolaryngological disorders.

---

### Guest Editors

Dr. Faris F. Brkic

Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria

Prof. Dr. Wolf-Dieter Baumgartner

Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria

---

### Deadline for manuscript submissions

closed (20 October 2025)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/186223](https://mdpi.com/si/186223)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).